Blood glucose level during induction phase chemotherapy in childhood acute lymphoblastic leukemia

Main Article Content

Nunki Andria
Annang Giri Moelyo
Muhammad Reza


Background Steroids and L-asparaginase (L-Asp) are agents used in induction phase chemotherapy for childhood acute lymphoblastic leukemia (ALL). Both agents are often reported to have the side effect of hyperglycemia, and native L-Asp is also reported to cause hypoglycemia. In ALL patients, hyperglycemic events during chemotherapy can cause lower 5-year overall and relapse-free survival.

Objective To investigate the incidence of abnormal blood glucose level (BG) as the side effect of prednisone and L-Asp during induction phase chemotherapy, its  predisposing factors, and its effect on remission status.

Methods This cohort prospective study was conducted in 36 children aged 1-18 years who were newly diagnosed with childhood ALL at Dr. Moewardi Hospital, Surakarta, Central Java. Subjects’ nutritional status consist of wellnourished and undernourishment. Subjects underwent BG monitoring. At the end of induction phase chemotherapy, subjects underwent bone marrow puncture (BMP) evaluation to assess their response to chemotherapy and the effect of abnormal BG on remission status.

Results Hypoglycemia, a combination of hypoglycemia and hyperglycemia, hyperglycemia, as well as euglycemia, were experienced by 9, 7, 6, and 14 subjects, respectively. Nutritional status was found to be a significant risk factor for abnormal BG. There was no significant difference in remission status at the end of induction phase chemotherapy between the euglycemic group and abnormal BG groups (P=0.533).

Conclusion Abnormal BG during induction phase chemotherapy did not affect remission status at the end of induction phase.  Undernourishment is also found to be a predisposing factor in abnormal BG.

Article Details

How to Cite
Andria N, Moelyo A, Reza M. Blood glucose level during induction phase chemotherapy in childhood acute lymphoblastic leukemia. PI [Internet]. 29Jul.2020 [cited 25Sep.2020];60(4):197-. Available from:
Pediatric Hemato-Oncology
Received 2020-02-10
Accepted 2020-07-29
Published 2020-07-29


1. Tasian SK, Loh ML, Hunger SP. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer. 2015;121:3577-90. DOI: 10.1002/cncr.29573.
2. Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60:4-12. DOI: 10.1111/ped.13457.
3. Drucis M, Irga-Jaworska N, Mysliwiec M. Steroid-induced diabetes in the paediatric population. Pediatr Endocrinol Diabetes Metab. 2018;2018:136-9. DOI: 10.5114/pedm.2018.80995.
4. Tamez-Perez HE, Quintanilla-Flores DL, Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Tamez-Pena AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6:1073-81. DOI: 10.4239/wjd.v6.i8.1073.
5. Thu Huynh V, Bergeron S. Asparaginase toxicities: identification and management in patients with acute lymphoblastic leukemia. Clin J Oncol Nurs. 2017;21:E248-59. DOI: 10.1188/17.CJON.E248-E259.
6. Zhang BH, Wang J, Xue HM, Chen C. Impact of chemotherapy-related hyperglycemia on prognosis of child acute lymphocytic leukemia. Asian Pac J Cancer Prev. 2014;15:8855-9. DOI: 10.7314/apjcp.2014.15.20.8855.
7. Panigrahi M, Swain TR, Jena RK, Panigrahi A. L-Asparaginase-induced abnormality in plasma glucose level in patients of acute lymphoblastic leukemia admitted to a tertiary care hospital of Odisha. Indian J Pharmacol. 2016;48:595-8. DOI: 10.4103/0253-7613.190762.
8. Unit Koordinasi Kerja Hematologi Onkologi Ikatan Dokter Anak Indonesia. Buku Panduan Protokol Nasional Leukemia Limfoblastik Akut. Yogyakarta: Ikatan Dokter Anak Indonesia; 2018
9. Craig ME, Jefferies C, Dabelea D, Balde N, Seth A, Donaghue KC. ISPAD Clinical Practice consensus Guidelines 2014. Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2014;15:4-17. DOI: 10.1111/pedi.12186.
10. Ly TT, Maahs DM, Rewers A, Dunger D, Oduwole A, Jones TW, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2014;20:180-92. DOI: 10.1111/pedi.12174.
11. Sjarif DR. Prinsip asuhan nutrisi pada anak. In: Sjarif DR, Lestari ED, Mexitalia M, Nasar, SS, editors. Buku ajar nutrisi pediatrik dan penyakit metabolik. Jakatra: Badan Penerbit IDAI; 2011. p. 39.
12. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541-52. DOI: 10.1056/NEJMra1400972.
13. Maloney KW, Gore L. Agents in development for childhood acute lymphoblastic leukemia. Pediatr Drugs. 2018;20:111-20. DOI: 10.1007/s40272-017-0268-7.
14. Lowas SR, Marks D, Malempati S. Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;52:814-8. DOI: 10.1002/pbc.21980.
15. Aisyi M, Andariastuti M, Kurniati N. The effect of combination of steroid and L-asparaginase on hyperglycemia in children with acute lymphoblastic leukemia (ALL). Asian Pac J Cancer Prev. 2019;20:2619-24. DOI: 10.31557/APJCP.2019.20.9.2619.
16. Tanaka R, Osumi T, Miharu M, Ishii T, Hasegawa T, Takahashi T, et al. Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case report. Exp Hematol Oncol. 2012;1:8. DOI: 10.1186/2162-3619-1-8.
17. Misgar RA, Laway BA, Rahaman SH, Wani Al, Bashir MI, Bhat JR. L-asparaginase induced hypoglycemia in a case of acute lymphoblastic leukemia: a patient report. J Pediatr Endocrinol Metab. 2015;28:439-41. DOI: 10.1515/jpem-2014-0227.
18. Tsai MC, Huang HH, Chou YY, Cheng CN, Chen JS, Lin SJ. Risk factors for hyperglycemia during chemotherapy for acute lymphoblastic leukemia among Taiwanese Children. Pediatr Neonatol. 2015;56:339-45. DOI: 10.1016/j.pedneo.2015.01.008.
19. Francis NK, Pawar HS, Mitra A, Mitra A. Assessment of insulin sensitivity and its convalescence with dietary rehabilitation in undernourished rural west Bengal population. J Clin Diagn Res. 2017;11:29-32. DOI: 10.7860/JCDR/2017/25888.9937.